ArticleJournal of nanobiotechnology2026
S2P-modified PLGA bifunctional nanodrug: inhibiting vascular senescence and foam cell formation for atherosclerosis treatment.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The progression of atherosclerosis (AS) is closely related to endothelial senescence and abnormal lipid metabolism in macrophages. Although metformin (Met) can exert vascular endothelial protective effects by inhibiting endothelial cell senescence, the drug exhibits limited capacity to regulate lipid metabolism. In contrast, evolocumab (Evol), a PCSK9-specific inhibitor, can lower LDL-C levels to reduce foam cell formation. This study takes pathological endothelial cells and macrophages as core targets. Leveraging the complementary between Met-mediated anti-endothelial senescence and Evol-regulated lipid metabolism, S2P peptide-modified PLGA nanocarriers (S-P@(Met + Evol) NPs) were constructed to achieve co-delivery of the two drugs, further enhancing the dual-targeting function of the nanomedicine. In vitro studies showed that S-P@(Met + Evol) NPs effectively reduced oxidative damage, inhibited vascular aging and enhanced macrophage cholesterol efflux. In vivo studies showed that this nanodrug significantly alleviated aging damage, lipid accumulation, and inflammatory responses, synergistically reduced plaque burden, enhanced plaque stability, and exhibited a good safety profile. In conclusion, this dual-cell targeted synergistic regulation strategy provides an effective approach for the treatment of AS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.